Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

The stock market can be quite turbulent. Growth stocks, while having tremendous potential, can also be risky, as we have seen this month. The once-hyped AI growth stocks plummeted as investors failed to see adequate growth in comparison to their enormous capital expenditures. In such volatile scenarios, dividend stocks turn out to be a reliable source of income. When it comes to dependable income, few names carry the weight of Pfizer (PFE). After a rocky few years highlighted by post-pandemic revenue stabilization and pipeline shifts, PFE stock now offers something income investors rarely ignore: a dividend yield above 6%.

Fundamentals

See More
  • Market Capitalization, $K 154,025,824
  • Shares Outstanding, K 5,685,708
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,118 M
  • EBITDA $ 26,131 M
  • 60-Month Beta 0.47
  • Price/Sales 2.47
  • Price/Cash Flow 6.63
  • Price/Book 1.66

Options Overview Details

View History
  • Implied Volatility 23.83% (-0.33%)
  • Historical Volatility 24.71%
  • IV Percentile 34%
  • IV Rank 16.44%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 8) 0.62 (2.29%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 61,547
  • Volume Avg (30-Day) 150,017
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 2,606,405
  • Open Int (30-Day) 2,702,179
  • Expected Range 26.48 to 27.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.78
  • Number of Estimates 6
  • High Estimate 0.92
  • Low Estimate 0.64
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -15.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.26 +7.28%
on 02/03/26
27.94 -3.01%
on 02/13/26
+1.22 (+4.71%)
since 01/26/26
3-Month
24.83 +9.14%
on 01/02/26
27.94 -3.01%
on 02/13/26
+1.39 (+5.41%)
since 11/26/25
52-Week
20.92 +29.57%
on 04/09/25
27.94 -3.01%
on 02/13/26
+0.68 (+2.57%)
since 02/26/25

Most Recent Stories

More News
Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

Even amid volatility, Pfizer keeps rewarding shareholders year after year.

$SPX : 6,908.86 (-0.54%)
PFE : 27.10 (+0.04%)
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir ...

GSK.LN : 2,167.000 (-2.12%)
PFE : 27.10 (+0.04%)
Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects

XLV : 157.42 (-0.26%)
AMGN : 379.33 (-1.30%)
PFE : 27.10 (+0.04%)
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancer ...

PFE : 27.10 (+0.04%)
Is AbbVie Stock Underperforming the Dow?

Although AbbVie has lagged behind the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

$DOWI : 49,499.20 (+0.03%)
ABBV : 224.69 (-0.98%)
PFE : 27.10 (+0.04%)
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

HELP : 7.76 (+0.91%)
CMPS : 7.33 (-1.48%)
PFE : 27.10 (+0.04%)
TAK : 18.53 (-0.43%)
BMY : 61.10 (-0.33%)
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio   This news release...

HELP : 7.76 (+0.91%)
LLY : 1,022.02 (-0.66%)
PFE : 27.10 (+0.04%)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care...

PFE : 27.10 (+0.04%)
Option Volatility And Earnings Report For February 23 - 27

Earnings season is winding down, but all eyes will be on Nvidia (NVDA) this Wednesday in what could be a market shaping announcement.

NVDA : 184.89 (-5.46%)
SNOW : 173.06 (+2.28%)
BIDU : 125.15 (-5.65%)
PFE : 27.10 (+0.04%)
O : 66.60 (+0.92%)
DIS : 105.55 (+0.48%)
IREN : 44.24 (+0.48%)
CRWV : 97.63 (-0.39%)
TSLA : 408.58 (-2.11%)
QCOM : 145.59 (-0.16%)
WBD : 28.80 (-0.35%)
CME : 316.45 (+2.96%)
2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off

2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off

MO : 69.47 (-0.33%)
FISV : 61.89 (+0.45%)
PFE : 27.10 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 27.69
2nd Resistance Point 27.48
1st Resistance Point 27.29
Last Price 27.10
1st Support Level 26.89
2nd Support Level 26.68
3rd Support Level 26.49

See More

52-Week High 27.94
Last Price 27.10
Fibonacci 61.8% 25.26
Fibonacci 50% 24.43
Fibonacci 38.2% 23.60
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar